ConocoPhillips continues its post-earnings climb, but the options market has turned notably more defensive even as the analyst upgrade cycle rolls on — the sharpest divergence in the stock's positioning for months.
The clearest signal this week is in options. The put/call ratio has jumped to 0.85, more than two standard deviations above its 20-day average of 0.74 — a z-score of 2.44 that puts this reading among the more defensive postures COP has seen in the past year. That's a meaningful shift for a stock up 3% on the week and 13% over the past month, now trading at $129.72. Options traders are buying more downside protection even as the price continues to push higher. Short interest tells a quite different story: bears have been retreating, not building. SI dropped 18% in a single session on August 18 to 1.5% of the free float — a low level by any measure — and is down 9% over the past month. The borrow market confirms this is not a contested stock. Cost to borrow has eased to 0.26%, its lowest level in 30 days, and availability is effectively unconstrained, with lending supply vastly exceeding current demand. Overall positioning looks cautious in the options layer but not crowded on the short side.
The Street, meanwhile, has been busy resetting higher. Since the August 6 earnings print, Morgan Stanley lifted its target to $151 (Overweight), Argus moved to $153 (Buy), and UBS raised to $153 as well. Barclays trimmed slightly to $150 but kept its Overweight. The consensus mean now stands at $144.29, implying roughly 11% headroom from the current price — a narrower gap than the ~15% cushion that existed when the previous note was published, as the stock has continued to outrun revised estimates. Even Truist, the lone Hold-rated voice in the recent batch, lifted its target to $130 — barely above where COP is already trading. The direction of travel on the Street is still clearly upward, but the gap between price and target is compressing. The analyst recommendation differential factor scores at the 96th percentile, confirming the consensus skew is unusually bullish relative to the broader market. Valuation has drifted higher with the price: the P/E has expanded to 13.1x and price-to-book to 2.2x, both up materially over 30 days, though on an EV/EBITDA basis of 5.7x the stock still looks reasonably priced for its peer group.
The institutional holder base is anchored by the majors. BlackRock recently added roughly 2.7 million shares to reach 7.8% of the company. JP Morgan Asset Management added 2.8 million shares in the most recent reporting period. T. Rowe Price holds 4.1% and added 5.2 million shares. These are not high-conviction contrarian builds — they are index-adjacent flows from large passive and semi-active managers — but the direction of adjustment among the top holders is incrementally positive. The insider picture is less constructive in the near term: the most recent open-market trades on record are sells, including a $64.5 million disposal by outgoing CEO Ryan Lance in March. The bear case centres on this leadership transition and whether incoming CEO Tim O'Brien can maintain the acquisition track record Lance built; the bull case points to the fortress balance sheet, strong free cash flow, and a well-flagged succession that the Street appears broadly comfortable with.
The next earnings date is November 5. What to watch between now and then is whether the put/call ratio normalises back toward its 0.74 mean as the post-earnings rally digests, or continues to flag unease — and whether CVX and EOG, both up 4-5% on the week, sustain the sector bid that has been lifting the whole group.
See the live data behind this article on ORTEX.
Open COP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
